Mogamulizumab
drugOn this page
Also known as AMG-761KM-8761KM8761KW-0761Mogamulizumab (genetical recombination)Mogamulizumab kpkcMogamulizumab-kpkcPoteligeo
Summary
Mogamulizumab (CHEMBL1743041) is an approved antibody (ATC L01FX09) targeting CCR4; indicated across 12 conditions including neoplasm and sezary syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L01FX09
- Targets: 1 (CCR4)
- Indications: 12 conditions
- Clinical trials: 36
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1743041 |
| Name | Mogamulizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L01FX09 |
Also known as: AMG-761, KM-8761, KM8761, KW-0761, Mogamulizumab, Mogamulizumab (genetical recombination), Mogamulizumab kpkc, Mogamulizumab-kpkc, Poteligeo, MOGAMULIZUMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CCR4 | CCR4 | Inhibition | P51679 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): CCR4.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 1 | CCR4 |
| Signaling by GPCR | 1 | CCR4 |
| Class A/1 (Rhodopsin-like receptors) | 1 | CCR4 |
| Peptide ligand-binding receptors | 1 | CCR4 |
| Chemokine receptors bind chemokines | 1 | CCR4 |
| GPCR downstream signalling | 1 | CCR4 |
| G alpha (i) signalling events | 1 | CCR4 |
| GPCR ligand binding | 1 | CCR4 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| tolerance induction | 1 |
| chemotaxis | 1 |
| inflammatory response | 1 |
| immune response | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| calcium-mediated signaling | 1 |
| homeostasis of number of cells | 1 |
| cell chemotaxis | 1 |
| interneuron migration | 1 |
| neuron migration | 1 |
| signal transduction | 1 |
| cell surface receptor signaling pathway | 1 |
| G protein-coupled receptor signaling pathway | 1 |
| chemokine-mediated signaling pathway | 1 |
| cellular response to cytokine stimulus | 1 |
Indications & clinical
Indications
12 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| Sezary syndrome | 4 | MONDO:0017844 | EFO:1000785 |
| mycosis fungoides | 4 | MONDO:0009691 | EFO:1001051 |
| primary cutaneous T-cell non-Hodgkin lymphoma | 3 | MONDO:0000607 | EFO:0002913 |
| tropical spastic paraparesis | 3 | MONDO:0008039 | EFO:0007527 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| mature T-cell and NK-cell non-Hodgkin lymphoma | 2 | MONDO:0000430 | MONDO:0000430 |
| carcinoma | 1 | MONDO:0004993 | EFO:0000313 |
| hepatocellular carcinoma | 1 | MONDO:0007256 | EFO:0000182 |
| non-small cell lung carcinoma | 1 | MONDO:0005233 | EFO:0003060 |
| asthma | 1 | MONDO:0004979 | MONDO:0004979 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 36.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 14 |
| PHASE1 | 10 |
| PHASE1/PHASE2 | 6 |
| PHASE3 | 2 |
| Not specified | 2 |
| PHASE4 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06285370 | PHASE4 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
| NCT01728805 | PHASE3 | COMPLETED | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL |
| NCT03191526 | PHASE3 | TERMINATED | A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) |
| NCT04128072 | PHASE2 | RECRUITING | Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma |
| NCT04256018 | PHASE2 | RECRUITING | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome |
| NCT04930653 | PHASE2 | RECRUITING | Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma |
| NCT05956041 | PHASE2 | RECRUITING | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas |
| NCT05996185 | PHASE2 | RECRUITING | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma |
| NCT06698003 | PHASE2 | RECRUITING | A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 |
| NCT07529405 | PHASE2 | NOT_YET_RECRUITING | A Study of VG712 in Patients With Mycosis Fungoides |
| NCT00888927 | PHASE1/PHASE2 | COMPLETED | Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma |
| NCT00920790 | PHASE2 | COMPLETED | Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma |
| NCT01173887 | PHASE2 | COMPLETED | Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 |
| NCT01192984 | PHASE2 | COMPLETED | Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma |
| NCT01226472 | PHASE2 | COMPLETED | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 |
| NCT01611142 | PHASE2 | COMPLETED | Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) |
| NCT01626664 | PHASE2 | COMPLETED | KW-0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) |
| NCT02281409 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors |
| NCT02705105 | PHASE1/PHASE2 | COMPLETED | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors |
| NCT03309878 | PHASE1/PHASE2 | COMPLETED | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
| NCT04541017 | PHASE1/PHASE2 | TERMINATED | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment |
| NCT04676087 | PHASE1/PHASE2 | TERMINATED | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides |
| NCT04745234 | PHASE2 | UNKNOWN | Mogamulizumab Q4week Dosing in Participants With R/R CTCL |
| NCT04848064 | PHASE1 | RECRUITING | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma |
| NCT05414500 | PHASE1 | RECRUITING | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides |
| NCT00355472 | PHASE1 | COMPLETED | Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL |
| NCT01929486 | PHASE1 | UNKNOWN | Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer. |
| NCT02301130 | PHASE1 | COMPLETED | Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors |
| NCT02358473 | PHASE1 | COMPLETED | Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer |
| NCT02444793 | PHASE1 | TERMINATED | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors |
| NCT02867007 | PHASE1 | COMPLETED | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors |
| NCT02946671 | PHASE1 | COMPLETED | Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients |
| NCT04185220 | PHASE1 | COMPLETED | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome |
| NCT06235281 | EARLY_PHASE1 | SUSPENDED | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) |
| NCT05455931 | Not specified | ACTIVE_NOT_RECRUITING | Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) |
| NCT07132567 | Not specified | RECRUITING | Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
6 molecules share ≥1 primary target. Top 6 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CLOTRIMAZOLE | ChEMBL + PubChem | Phase 4 (approved) | CCR4 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | CCR4 |
| DISULFIRAM | ChEMBL | Phase 4 (approved) | CCR4 |
| ITRACONAZOLE | ChEMBL | Phase 4 (approved) | CCR4 |
| QUERCETIN | ChEMBL + PubChem | Phase 3 (approved) | CCR4 |
| Mavorixafor | PubChem | Approved | CCR4 |